At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 12, 2026 at 16:01 ET
Spero Therapeutics reported Q2 2026 financial results, highlighting a net loss of $11.0 million for the quarter, compared to a net loss of $10.7 million in the same period last year. The company ended the quarter with $60.7 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The results are largely neutral for a clinical-stage biotech with no approved products, as the focus remains on pipeline development rather than financial performance.
- Net loss of $11.0 million for Q2 2026, compared to $10.7 million in Q2 2025.
- Cash, cash equivalents, and marketable securities of $60.7 million as of June 30, 2026.
- Research and development expenses were $7.5 million for Q2 2026, down from $8.5 million in Q2 2025.
- General and administrative expenses were $4.2 million for Q2 2026, compared to $4.0 million in Q2 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access